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INTRODUCTION 
General anaesthesia is the induction of state of complete 
unconsciousness with loss of pain sensation over the entire body. 
The purpose of general anaesthesia are analgesia, amnesia, 
immobility, unconsciousness, skeletal muscle relaxation. Infants 
and young children respond to medications due to factors like body 
composition, protein binding, body temperature distribution of 
cardiac output, functional maturity of the liver and kidneys.  
Cochlear implantation surgery in a great advance in otology 
for patients with irreversible hearing loss. Anaesthetic management 
includes bloodless surgical field to facilitate microsurgery, efficient 
airway management, smooth recovery and post operative care 
without nausea and vomiting. 
The study was designed to evaluate the post operative 
recovery time by using infusion dose of Dexmedetomidine 
0.4mcg/kg/hr versus Fentanyl 1mcg/kg/hr in patients undergoing 
cochlear implantation surgery. 
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AIM OF THE STUDY 
 To compare the post operative recovery time by modified 
aldrete recovery score using Dexmedetomidine and Fentanyl 
in cochlear implantation surgery for pediatric patients. 
 To assess post operative pain by FLACC behavioural pain 
assessment scale 
 To assess intraoperative hemodynamics. 
 To assess the quality of the surgical field. 
 To assess need for rescue analgesia and antiemetic in PACU.  
General Anaesthesia: Paediatric patients present unique 
anatomic, physiologic and pharmacologic consideration for 
the management of anaesthesia. 
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ANATOMY OF PAEDIATRIC AIRWAY 
Paediatric airway is more susceptible to upper airway 
obstruction because of large occiput which cause neck flexion, 
large tongue, increased soft tissue and flexible trachea can 
produced pressure on the tracheal ring leading to obstruction, 
cricoid pressure can cause tracheal collapse and obstruction. 
Visualization of airway and endotracheal intubation is difficult 
because of large tongue high and more anterior airway, more acute 
angle between tracheal opening and epiglottis, narrowest diameter 
at cricoid ring high and anterior larynx at level of C3-C4. 
GUEDEL’S STAGES OF ANAESTHESIA  
Stage-I (Statge of analgesia or discrimination)  from 
beginning of induction of general anaesthesia to loss of 
consciouness. 
Stage-II (Stage of excitement or delirium)  from loss of 
consciousness to onset of automatic breathing. Eyelash reflex 
disappear but other reflexes remain intact. 
Stage-III (Stage of surgical anaesthesia) from onset of 
automatic respiration to respiratory paralysis. 
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Stage-IV from stoppage of respiration till death. Anaesthetic 
overdose cause medullar paralysis with respiratory arrest and 
vasomotor collapse. 
CHOICE OF ANAESTHESIA 
General Anaesthesia preferred due to 
 Surgery under microscope visualisation 
 Pediatric patients 
 Long duration of surgery 
ADVANTAGES OF GENERAL ANAESTHESIA  
 Reduces intraoperative awareness and recall. 
Complete control of the airway breathing. 
 Can be reversible. 
 Allow proper muscle relaxation. 
DISADVANTAGES OF GENERAL ANAESTHESIA  
Can induce physiologic fluctuations that require active 
intervention. 
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Associated with loss serious complication such as nausea or 
vomiting, sore throat, shiwering, headache, delayed return to 
normal mental functioning. 
PAEDIATRIC VITAL SIGNS  
Age Pulse/min Respiration Systolic BP mmHg 
Birth-6 months 140-150 40 60-80 
6 month-1 year 110-140 30-40 80-90 
1-3 years 100-110 25-30 90 
3-4 years 95-100 25 100 
5-10 years 90-95 24 100-110 
NPO GUIDELINES  
Age Fasting time 
Milk and Solids(hr) Clear Fluids (hr) 
<6 months 4 2 
6 months- 3years 6 3 
>3 years 8 3 
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PRE OPERATIVE ASSESSMENT 
 Presence of any congenital abnormalities 
 Cerebral palsy 
 Developmental milestones 
 Active upper respiratory infections 
 Any neuromotor deficits 
Premedication 
The goal of premedication are to facilitate a smooth 
separation from the parents, to have the patient arrive in the 
operating room in a calm, relaxed frame of mind. Effects achieved 
by premedication include anxiolysis, prevention of physiologic 
stress, decreased salivation and secretions and antiemesis.  
INDUCTION  
Induction can be achieved by intravenous injection of 
induction agents, by the slower inhalation of anaesthetic vapour 
delivered into a face mask or by a combination of both. 
Sevoflurane (fluoromethyl 2,2,2-trifluro-l-(trifluromethyl) ethyl 
ether an inhalational anaesthetic agent with low blood solubility, 
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less pungent. Induction of anaesthesia is more rapid and recovery is 
also more rapid. 
Propofol (2,6-diisopropylphenol) exerts hypnotic actions by 
activation of the central inhibitory neurotransmitter GABA. An 
induction dose of 2-2.5mg/kg produces a 25% to 40% reduction of 
systolic blood pressure, mean and diastolic blood pressure. This 
effect is due to arterial vasodilation due to reduced vascular 
sympathetic tone. 
Intubation 
Laryngoscopy and tracheal intubation in anaesthetized 
children is associated with hypertension and tachycardia due to 
reflex sympathetic activation. Endotracheal tube placement should 
be confirmed by auscultation and end tidal capnography. 
Formula for selection of endotracheal tube  
For children <6 year of age =Age/3 + 3.5= ETT ID in mm 
Depth of insertion for oral ETT=10.5+wt (kg)/2 
     or  Age + 10cm 
Maintenance of intraoperative IV fluids. 
Holliday and segar formula 
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0-10kgs : 4ml/kg/hr 
10-20kgs : 40+2ml/kg/hr 
>20 Kgs : 60+1ml/kg/hr 
Extubation 
After surgery, patients was positioned on his or her lateral 
side. After oropharynx was gently sunctioned, the tracheal tube cuff 
was deflated. Once spontaneous respiratory pattern was confirmed 
by ETCO2 monitoring, the endotracheal tube was removed gently 
and quickly oxygen (6L/min) was administered via a facemask 
immediately after extubation. 
Complications associated with anaesthetic technique 
Post operative nausea and vomiting 
Respiratory depression 
Post operative hypoxaemia 
Emergence delirium 
Sore throat 
Post extubation croup 
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Post operative pulmonary oedema 
Hepatic dysfunction 
CONGENITAL SYNDROMES ASSOCIATED WITH DEAF 
MUTISM AND ANESTHETIC IMPLICATIONS 
Treacher Collins syndrome - associated with facial dysplasia can 
lead difficult airway management. 
Klippel fiel anomaly - restricted neck movement and difficult 
intubation. 
Pendred syndrome - goitre and hypothyroidism 
Jervell and Lange Nielsen syndrome - prolonged QT interval, 
ventricular arrhythmia 
Usher syndrome - Impaired vision because of congenital cataract 
Alport syndrome - associated with endocrine abnormalities and 
renal failure 
PHARMACOLOGY OF DEXMEDETOMIDINE 
Highly selective  2 adrenergic agonist which produces 
sedation hypnosis and analgesia.  
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STRUCTURE OF DEXMEDETOMIDINE 
 
Chemistry 
4(CS)-alpha 2,3- Trimethylbenzyl) imidazole 
Dexmedetomidine Hydrochloride is the S-enantiomer of 
medetomidine. 
Chemically described as (+)- 4- (S)- [1- (2,3-dimethylphenyl) 
ethyl]-1H- imidozolemono hydrochloride. 
Molecular weight: 236.74 
Molecular formula: C13H16N2Hcl 
Pharmacological Profile 
Highly selective 2 adrenergic agonist which shows a high 
ratio of specificity for the 2 receptor. Dexmedetomidine belongs 
to the imidazole subclass of 2 agonist. It is highly water soluble 
and is available as a preservative free and parenteral formulation. 
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Pharmacokinetics 
T ½-6 minutes. It is 94% protein bound. 
METABOLISM 
Dexmedetomidine undergoes biotransformation by 
conjugation (41%) N-methylation (21%) or hydroxylation followed 
by conjugation in liver. The inactive metabolities are excreted in 
urine and feces. The elimination half life of Dexmedetomidine is 
two (2) to three (3) hours. Pharmacokinetics are similar in young 
adults and elderly.  
MECHANISM OF ACTION 
Dexmedetomidine is a highly selective 2 agonist. 3 types of 
2 adreno receptors in humans are 2A, 2B, 2C. The 2A 
adrenoreceptor are located in the periphery where as 2B and 2C 
receptors are located in the brain and spinal cord. 
Presynaptic activation of 2 adrenoreceptors inhibits the release of 
nor epinephrine and postsynaptic activation inhibits sympathetic 
activity and decreases blood pressure and heart rate producing 
sedation and anxiolysis. 
Binding of Dexmedetomidine to 2 adrenergic receptors in 
the spinal cord produces analgesia. 
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Action of Dexmedetomidine on 2 receptors in the locus 
ceruleus produces sedation and hypnosis and action on 2 receptors 
with in the locus ceruleus and with in the spinal cord produces 
analgesic effect. 
ACTIONS 
Effects on the central nervous system 
SEDATION 
The 2 agonist exert their sedative effect by acting on the 
endogenous sleep-promoting pathways. 
Although it produces good sedative effect, patient can be 
arousable alert and able to respond without any discomfort. It 
produces limited respiratory depression. 
ANALGESIA 
The primary site of action is thought to be spinal cord when 
injected through the intrathecal or epidural route. 
Systemic use of Dexmedetomidine shows norcotic sparing. The 
requirement of narcotics were reduced by 50% in patient, receiving 
Dexmedetomidine. 
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EFFECTS ON THE RESPIRATORY SYSTEM 
The concentrations of Dexmedetomidine which produces 
sedation reduces minute ventilation but retains hyper capnic 
ventilation response. 
EFFECTS ON THE CARDIOVASCULAR SYSTEM  
Effects on the cardiovascular system produces decreased 
heart rate, decreased systemic vascular resistance and thereby 
decreases myocardial contractility and systemic Blood Pressure. 
Dexmedetomidine produces an initial increase in Blood pressure 
which occur 5 mins afte administration due to the vasoconstrictive 
effects on peripheral receptors followed by decreased in Blood 
Pressure due to action on central 2 adrenoreceptor activity. 
Administration of loading dose of Dexmedetomidine increases the 
incidence of hypotension and bradycardia. So avoiding the loading 
dose upto 0.4mcg/kg reduces the incidence of Hypotension. 
DOSAGE AND ADMINISTRATION 
Dexmedetomidine is supplied in 1 ml ampoule 50mcg/ml and 
2ml ampoule 100mcg/ml. 
Loading dose-0.5-1.0mcg/kg over 10min 
Maintenance dose -0.3-0.7mcg/kg/hr. 
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USES 
1. INTENSIVE CARE UNIT: 
Dose requirement for opioids get reduced by >50% when 
compared with propofol or benzodiazepines in patients receiving 
Dexmedetomidine. 
Dexmedetomidine produces adequate sedation with minimal 
respiratory depression. 
Dexmedetomidine also used in the treatment of alcohol 
withdrawal and withdrawal of narcotics, benzodiazepines and 
recreational drugs. 
2.ANAESTHESIA 
 Dexmedetomidine attenuates the hemodynamic response to 
intubation when given 10-15 minutes before induction in the 
dose of 0.3-0.67mcg/kg. 
 Used for securing the airway during fibreoptic intubation. 
 As an anaesthetic adjuvant in sleep apnea patients, bariatric 
surgery, CABG surgery, vascular surgery, evoked potential 
study, thoracic surgery. 
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CONTRAINDICATIONS 
Infusion over 24 hours. 
In caesarean deliveries. 
In patients with ejection fraction <30%. 
Patients with preexisting bradycardia and bradyarrrhythmias.  
Hypotensive or hypovolemic patients. 
Patients with raised intracranial tension. 
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PHARMACOLOGY OF FENTANYL 
Fentanyl is a potent lipophilic synthetic opiod. Fentanyl is a  
receptor agonist with a short onset time and moderate duration of 
action. Sufentanyl and alfentanyl are derived from the Fentanyl 
citrate which is the synthetic parent opioid. 
CHEMISTRY 
 
C22H28N20C6H807 
N-Phenyl-N-[1(2-phenylethyl)-4Piperidinyl] Propanamide citrate. 
The Phenylpiperidine (synthetic) opioid 
Fentanyl skeleton structure 
Molecular weight (free base) - 528.5 (336.5) 
Pka (amino)- 8.43 
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SOLUBILITY 
In alcohol       - 1 in 140 
In water       - 1 in 40 
Octonol/ Water partition coefficient - 955 
Fentanyl,  agonist which has a more rapid onset and shorter 
duration of action than morphine. It has the greater lipid solubility 
compared with that of morphine. 
Fentanyl produces dose related analgesia. Fentanyl in the 
dose of 0.5-3mcg/kg used as a supplement in spontaneously 
breathing anaesthetized patients. Fentanyl 5mcg/kg will suppress 
somatic and autonomic responses to surgical stimulation in 
ventilated patients. Fentanyl in the doses of 50mcg/kg may be used 
to induce and maintain anaesthesia. 
Fentanyl reduces brain stem respiratory responsiveness to 
Co2 as it is a potent respiratory depressant. Fentanyl has little 
effects on the circulation. It produces vagally mediated bradycardia 
and slight fall in systemic vascular resistance. 
The effect of skeletal muscle rigidity and clonic movements which 
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binder mechanical ventilation is reversed by nalaxone and 
overcome by neuromuscular blocking  drugs. 
Fentanyl causes reduction in metabolic activity and oxygen 
consumption. Nausea and vomiting may be produced. Itching of the 
nose, cough suppression, pupillary constriction may also occur. 
Fentanyl may increase intracranial pressure in patients with severe 
head injury. It lowers the cerebral perfusion pressure. Fentanyl will 
reduce intra ocular pressure. 
Relative contraindications for Fentanyl are 
1. Raised ICP 
2. Hypovolemia 
3. Respiratory inadequacy 
Pharmacokinetics 
There are three- compartment model used to describe decay 
of plasma fentanyl concentration. Approximately 75 percent of an 
injected dose of Fentanyl was taken up by the lungs for first pass 
metabolism. 
Volume of distribution (3-6Lkg–1) and clearance (10-20ml Kg–1 
min–1) are high for fentanyl.  
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Approximately 80% of fentanyl which is bound to plasma 
proteins are taken up by the red blood cells (40%). It exists in the 
ionized form (>90%) as the pka of fentanyl is high (8.4) at 
physiological pH. Fentanyl has high lipid solubility and large 
volume of distribution. The tissue/ blood partition coefficient of 
fentanyl is 2-30 fold higher than alfentanyl. It gets metabolized in 
the liver. Because of its wide distribution in body tissues, Fentanyl 
is relatively long acting. 
Fentanyl gets metabolized in the liver by -dealkylation and 
hydroxylation. Because of high  hepatic clearance and high hepatic 
extraction ratio, metabolism starts by 1.5 min after injection. 
Norfentanyl, the primary metabolite, is detectable in urine for upto 
48 hours after IV fentanyl. Little fentanyl is excreted in the urine 
unchanged.  
FACTORS WHICH ALTER PHARMACOKINETICS AND 
PHARMACODYNAMICS 
 Age: In neonates, the elimination of fentanyl takes long 
period, pharmacokinetics which changes with advanced age, 
may play a minor role. 
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 Weight: pharmacokinetics does not change in lean and obese 
patients. 
Renal failure: The clinical importance of kidney failure is less 
marked. 
 Hepatic failure: Decrease in the fentanyl plasma 
concentration will be delayed in the hepatic failure. 
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REVIEW OF LITERATURE 
1.Mohamed Hafez El Saied et al
6
 (Egyptian Journal of 
Anaesthesia 2015 vol 32 p55-59) studied the Anesthesia for cochlear 
implantation in pediatrics mandates deliberate hypotension to provide 
a better surgical field. Dexmedetomidine is α2  adrenoceptor agonist 
that provides adequate sedation with high cardiovascular stability. We 
aimed to compare it with fentanyl as an anesthetic adjuvant. 52 
pediatric patients (ASA I or II), undergoing cochlear implantation 
were randomized into dexmedetomidine (D) group and fentanyl (F) 
group (n = 26 for each). Anesthesia was induced by I.V. 
dexmedetomidine in (D) group at a bolus dose of 0.4 μg/kg slowly 
infused over 10 min, then continuous infusion by a rate of 0.4 μg/kg/h 
until the end of surgery. In (F) group; anesthesia was induced by I.V. 
fentanyl at a dose of 1 μg/kg over 10 min, then continuous infusion by 
a rate of 1 μg/kg/h. This is followed by I.V. propofol and atracurium 
for both groups. Maintenance was done without additional muscle 
relaxant to allow monitoring of the facial nerve. Both groups were 
compared as regards the quality of the surgical field, intraoperative 
hemodynamics, recovery and discharge time, postoperative pain using 
objective pain score and the need for rescue analgesics and anti-
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emetics in postanesthesia care unit (PACU). Dexmedetomidine group 
showed a decreased heart rate and mean arterial pressure than 
fentanyl group. These parameters were significantly decreased 
compared to the baseline throughout the procedure in D group. The 
quality of the surgical field was significantly better in D group than in 
F group. Postoperative pain and complications were not different 
between the two groups. Recovery and discharge time was 
significantly shorter for the patients in D group than in F group 
(p < 0.05).Dexmedetomidine infusion in cochlear implantation in 
pediatric patients was better in inducing deliberate hypotension and 
providing better quality scale of surgical field compared to fentanyl 
infusion. It allowed rapid recovery from anesthesia and reduced need 
for pain medication in the PACU. 
2.Gupta N, et al
10
. (J Neurosurg Anesthesiol. 2013.) 
conducted study in Thirty-six children with spinal dysraphism at 
lumbosacral area, aged 8 to 12 years, undergoing corrective surgery 
were randomized to receive either dexmedetomidine or volume-
matched saline (placebo) after positioned prone until beginning of 
skin closure. Inspired concentration of sevoflurane was changed to 
keep the bispectral index score between 45 and 55. Perioperative 
hemodynamics, intraoperative fentanyl and sevoflurane 
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consumption, and postoperative recovery profile and fentanyl 
consumption was observed by blinded observers. Postoperative 
pain, emergence agitation (EA), and discharge readiness from 
postanesthesia care unit was evaluated using the modified objective 
pain score, agitation Cole score, and modified Aldrete score, 
respectively. Fentanyl 0.5-1 µg/kg was administered for pain 
(objective pain score ≥4) or severe EA (agitation Cole score ≥4) 
lasting for >5 minutes. The 2 groups did not differ significantly 
with respect to demographics, duration of anesthesia, emergence, 
and extubation times. The intraoperative consumption of 
sevoflurane and fentanyl was significantly less in dexmedetomidine 
group (0.2±0.1 vs. 0.3±0.1 mL/min, P<0.0001 and 2.3±0.5 vs. 
3.1±0.6 μg/kg, P=0.0001, respectively), along with a lower mean 
heart rate (P<0.001). The mean systolic blood pressure (P=0.98) 
and incidence of bradycardia and hypotension was comparable in 
between the 2 groups. Postoperatively, the children in 
dexmedetomidine group had significantly lower pain scores 
(P<0.0001), agitation scores (P<0.0001), and time to achieve full 
modified Aldrete score [0 (0 to 10) vs. 10 (0 to 20) min, P=0.001]. 
The postoperative consumption of fentanyl was significantly less in 
dexmedetomidine group [0 (0 to 1.04) vs. 0.88 (0 to 3) µg/kg, 
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P=0.003], along with a longer time of first analgesic requirement 
[600 (5 to 2100) vs. 5 (5 to 185) min, P=0.0001]. The mean heart 
rate and systolic blood pressure were higher in placebo group 
(P<0.001), whereas no difference was observed in respiratory rate 
(P=0.73) and arterial oxygen saturation (P=0.36). The number of 
patients with postoperative nausea and vomiting was significantly 
lower in dexmedetomidine group [2 (11.1%) vs. 9 (50%), P=0.03].  
Intraoperative use of dexmedetomidine in children undergoing 
spinal surgery results in a favorable recovery profile with reduced 
postoperative pain and EA, without adverse perioperative 
hemodynamic effects. 
3.Goyal S, et al
9
 (Anesth Essays Res. 2017 Jul-Sep.) 
conducted the study to compare the efficacy of dexmedtomidine 
with fentanyl in breast cancer surgery in terms of haemodynamic 
stability, anaesthetic sparing effects, recovery profile and 
postoperative analgesia. randomized prospective controlled trial, a 
total of 60 female patients were randomly assigned into two groups. 
Patients in group F (n = 30) received a loading dose of fentanyl 2 
μg/kg with maintenance dose of 0.5 μg/kg/h and in group D (n = 
30) received dexmedetomidine 1 μg/kg as loading dose with 
maintenance dose of 0.25 μg/kg/h till the end of surgery. 
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Hemodynamic parameters, desflurane requirement, recovery profile 
and postoperative analgesia were monitored and compared in both 
the groups. Mean HR was less in group D compared to group F 
intraoperatively, before and after extubation with a significant p 
value. The mean MAP was also lower in group D compared to 
group F at all the time points. MAC requirements were found lower 
in group D compared to group F with a significant P < 0.001. 
Cognitive recovery in the form of time to respond to verbal 
commands, time to extubation, time to orientation was early in 
dexmedetomidine group. Dexmedtomidine can be used as suitable 
alternative to fentanyl in breast cancer surgeries due to better 
hemodynamic stability, anaesthetic sparing effects and better 
recovery profile. 
4.Passaint Fahim Hassan, Amany Hassan Saleh et al 7 
(Anesthesia Essays and Researches) aimed to compare both 
dexmedetomidine and magnesium sulfate as regards their efficacy 
in inducing deliberate hypotension and providing better quality of 
the surgical field during cochlear implantation in 
pediatrics. Prospective, randomized double-blinded study. Forty-six 
pediatric patients aging 1.5–2.5 years of either sex with American 
Society of Anesthesiologists physical status classes I and II were 
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randomized into dexmedetomidine (D) group (n = 23) and 
magnesium sulfate (M) group (n = 23). In the D group, after 
induction of anesthesia but before the surgery, a bolus dose of 0.4 
μg/kg slowly infused over 10 min, then continuous infusion by a 
rate of 0.4 μg/kg/h until the end of surgery. In M group, after 
induction of anesthesia but before the surgery, magnesium sulfate 
10% (50 mg/kg) was given slowly, then continuous infusion by a 
rate of 10 mg/kg/h during the whole surgery. Intraoperative 
hemodynamics, quality of surgical field, fentanyl consumption, 
blood loss, operative time, FLACC pain scores, and adverse effects 
were compared in both groups. Surgical field score and blood loss 
were better in D group than M group. Fentanyl consumption was 
less in D group than M group. Heart rate and mean atrial blood 
pressure were lower in D group except in the initial times than M 
group.In our study, both drugs were effective in achieving 
hypotensive anesthesia in pediatrics; however, dexmedetomidine 
proved to have superior effect on the surgical field and blood loss 
compared to magnesium sulfate with no intra- and post-operative 
complications for cochlear implantation surgery.  
5.Aynur Akin,Adnan Bayram, Aliye Esmaoglu
4 
(Pediatric 
Anesthesia Volume 22,p 871–876)conducted the study of 
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Dexmedetomidine vs midazolam for premedication of pediatric 
patients undergoing anesthesia. Dexmedetomidine, an α2-receptor 
agonist, provides sedation, analgesia, and anxiolytic effects, and 
these properties make it a potentially useful anesthetic 
premedication. In this study, we compared the effects of intranasal 
dexmedetomidine and midazolam on mask  Ninety induction and 
preoperative sedation in pediatric patients. children classified as 
ASA physical status I, aged between 2 and 9, who were scheduled 
to undergo an elective adenotonsillectomy, were enrolled for a 
prospective, randomized, and double-blind controlled trial. All of 
the children received intranasal medication approximately 45–
60 min before the induction of anesthesia. Group M (n = 45) 
received 0.2 mg·kg−1 of intranasal midazolam, and Group D 
(n = 45) received 1 μg·kg−1 of intranasal dexmedetomidine. All of 
the patients were anesthetized with nitrous oxide, oxygen, and 
sevoflurane, administered via a face mask. The primary end point 
was satisfactory mask induction, and the secondary end points 
included satisfactory sedation upon separation from parents, 
hemodynamic change, postoperative analgesia, and agitation score 
at emergence.Satisfactory mask induction was achieved by 82.2% 
of Group M and 60% of Group D (P = 0.01). There was no evidence 
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of a difference between the groups in either sedation score 
(P = 0.36) or anxiety score (P = 0.56) upon separation from parents. 
The number of patients who required postoperative analgesia was 
higher in Intranasal dexmedetomidine and the midazolam group 
(P = 0.045). midazolam are equally effective in decreasing anxiety 
upon separation from parents; however, midazolam is superior in 
providing satisfactory conditions during mask induction 
6.Hwang W, Lee J, Park J, Joo J et al
1
 (BMC 
Anesthesiol. 2015 Feb 24;15:21) studied the effect of  
Dexmedetomidine versus remifentanil in postoperative pain control 
after spinal surgery.TotalTotalTotalTotalTotal intravenous 
anesthesia (TIVA) is used widely in spinal surgery because 
inhalational anesthetics are known to decrease the amplitude of 
motor evoked potentials. Presently, dexmedetomidine is used as an 
adjuvant for propofol-based TIVA. We compared the effects of 
remifentanil and dexmedetomidine on pain intensity as well as the 
analgesic requirements after post-anesthesia care unit (PACU) 
discharge in patients undergoing spinal surgery.Forty patients 
scheduled for posterior lumbar interbody fusion (PLIF) surgery 
under general anesthesia were enrolled. Anesthesia was maintained 
using propofol at 3-12 mg/kg/h and remifentanil at 0.01-0.2 
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μg/kg/min in Remifentanil group or dexmedetomidine at 0.01 -0.02 
μg/kg/min in Dexmedetomidine group, keeping the bispectral index 
between 40 and 60. Patient-controlled analgesia (PCA) made of 
hydromophone was applied once the patients opened their eyes in 
the PACU. The visual analog scale (VAS) score, PCA dosage 
administered, and postoperative nausea and vomiting (PONV) were 
recorded at the time of discharge from the PACU (T1) and at 2 
(T2), 8 (T3), 24 (T4), and 48 hours (T5) after surgery 
The VAS score in Remifentanil group was significantly higher than 
that in Dexmedetomidine group at immediate and late postoperative 
period (4.1 ± 2.0 vs. 2.3 ± 2.2 at T1, and 4.0 ± 2.2 vs. 2.6 ± 1.7 
at T5; P < 0.05). Dexmedtomidine group had a statistically 
significantly lower PCA requirement at every time point after 
surgery except directly before discharge from the PACU (3.0 ± 1.2 
ml vs. 2.3 ± 1.4 ml at T1; P > 0.05, but 69.7 ± 21.4 ml vs. 
52.8 ± 10.8 ml at T5; P < 0.05). Patients in Remifentanil group 
displayed more PONV until 24 hours post-
surgery.Dexmedetomidine displayed superior efficacy in alleviating 
pain and in postoperative pain management for 48 hours after PLIF. 
Therefore, dexmedetomidine may be used instead of remifentanil as 
an adjuvant in propofol-based TIVA. 
 
30 
7.Dr. Marcia L. Buck, Douglas F. Willson et al
2
 (vol 28,p51-
57)conducted study to determine the safety, effectiveness, and 
dosing of dexmedetomidine in intensive care infants and children 
who require sedation, and the rationale for patient 
selection. Eleven-bed pediatric intensive care unit in a university-
affiliated children's hospital. Seventeen infants and children who 
received dexmedetomidine .Data were collected on demographics, 
blood pressure and heart rate measurements, and adverse effects. 
The rationale for dexmedetomidine use, its dosing, use of other 
sedatives, and treatment duration were also recorded. Twenty 
treatment courses in 17 patients (median age 5 mo, range 1 mo-17 
yrs) were evaluated. Ten patients (59%) had chronic neurologic 
impairments (including Down syndrome in nine [53%]). Thirteen 
(76%) had undergone cardiac surgery, two (12%) had respiratory 
failure, one (6%) had endocarditis, and one (6%) had undergone 
scoliosis repair. In 15 (75%) of 20 cases, dexmedetomidine was 
started to minimize the use of midazolam before extubation; in 13 
(87%) of these cases, the patients were extubated within 24 hours. 
The remaining patients could not tolerate midazolam, and 
dexmedetomidine was used as an alternative. No loading doses 
were given. The mean ± SD starting dose was 0.2 ± 0.2 μg/kg/hour, 
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with a maximum of 0.5 ± 0.2 μg/kg/hour. Mean ± SD duration was 
32 ± 21 hours (range 3–75 hrs); 10 courses exceeded 24 hours. 
Mean arterial pressures before and after starting treatment were not 
significantly different (p=0.76), nor were values at discontinuation 
(p=0.31) or 12 hours later (p=0.29). No significant differences were 
noted in heart rate at the start (p=0.09), at discontinuation (p=0.06), 
or 12 hours later (p=0.17). One patient (6%) developed 
hypotension; no other adverse effects were noted.With careful 
patient selection and a conservative approach to dosing, 
dexmedetomidine was a useful sedative in children requiring 
mechanical ventilation. It allowed for a reduction or elimination of 
other sedatives, and it was particularly useful in children with 
chronic neurologic impairments. Dexmedetomidine was well 
tolerated, with no clinically significant effects on blood pressure or 
heart rate. 
8.Sabry Mohamed Amin et al Mohamed Gamal Eldin 
Elmawy et al
5
 (Egyptian Journal of Anaesthesia 2016 vol 32 p255-
261) conducted the study to determine the efficacy of 
dexmedetomidine versus esmolol usage as an adjunct to induce 
controlled hypotension in children undergoing cochlear implan t 
surgery. 70 children aged 2–4 years scheduled for cochlear implant 
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surgery under general anesthesia. Patients were randomly allocated 
according to drugs used into two equal groups (35 patients in each 
group). Interventions: Group (D): The patients in this group 
received a bolus dose of dexmedetomidine 0.5 ug/kg over 10 min 
followed by continuous infusion 0.2–0.5 ug/kg/h after induction of 
anesthesia but before surgery. Group (E): The patients in this group 
received a bolus dose of esmolol 0.5 mg/kg over 10 min followed 
by continuous infusion 100–300 ug/kg/min after induction of 
anesthesia but before surgery.The quality of surgical field was 
comparable between both groups in all times of measurements. The 
time to first analgesic request was statistically significant longer in 
group (D) than in group (E) and the total tramadol consumption was 
statistically significant less in group (D) than in group (E).In our 
study both dexmedetomidine and esmolol were effective in 
reducing MABP, and lowering the heart rate providing dry surgical 
field and ensured good surgical condition during cochlear implant 
surgery in pediatric patients. 
9.Goksu S, Arik H, Demiryurek S et al
8
 (Eur J Anaesthesiol 
2008;25(1):22-8) conducted the study to investigate the 
haemodynamic effects of perioperatively administered 
dexmedetomidine, a new generation alpha-2-agonist, in patients for 
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functional endoscopic sinus surgery. Sixty-two patients who were 
planned to undergo functional endoscopic sinus surgery under local 
anaesthesia were included in the study. Following meperidine 
premedication, both groups were monitored in a standard manner 
with electrocardiogram, non-invasive blood pressure and 
percentages of peripheral saturation of oxygen. Saline intravenous 
infusion was started in the placebo group, and dexmedetomidine 
bolus intravenous infusion (an initial loading dose of 1 microg kg-1 
given for a 10-min period followed by 0.7 microg kg-1 h-1) was 
administered to the treatment group. Maintenance dose infusion 
was stopped 15 min before the end of the surgical procedure. 
Systolic, diastolic and mean arterial pressures, and heart rate 
markedly decreased in the dexmedetomidine group. However, 
dexmedetomidine had no effect on serum nitric oxide levels, 
measured by a nitric oxide/ozone chemiluminescence method. No 
significant difference was found in oxygen saturation levels of the 
two groups. Postoperative nausea and vomiting rates were 
significantly lower in the dexmedetomidine group. No adverse 
effects were observed with this alpha-2-agonist. Dexmedetomidine 
provided appropriate levels of sedation. 
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10.Jana JJ, Vaid N, Shanbhag J. (Cochlear Implants Int 
2013 Jun;14(3): 169-73) conducted the study to evaluate the effects 
of intravenous anaesthesia on intraoperative monitoring of cochlear 
implant function in paediatric cochlear implantees.study conducted 
in 29 children. Age - 18 months to 11 yrs. All children had bilateral 
severe to profound sensorineural hearing loss. Children with 
compromised neural/cochlear anatomy were excluded. Patients 
were maintained on an infusion of Fentanyl @ 0.3-0.6 ugm/kg/hr 
and Propofol @ 4-8 mg/kg/hr intraoperatively. Intraoperative 
measurements were done after performing the train of four test on 
the adductor pollicis muscle Results It was observed that ESRT was 
unaffected by intravenous anaesthesia. Electrical impedance and 
ECAP were not affected by any technique ofanaesthesia. 
Intravenous anaesthesia has little or no effect on the intraoperative 
auditory thresholds and is therefore recommended for determining 
these thresholds during cochlear implant surgery. 
11.Joseph S. Yeh, Kimberly L. Mooney, Kevin Gingrich  
(pediatric ears vol 121,P 2240-2244) 
Investigated the incidence of anesthetic complications in young 
patients undergoing general anesthesia for CI. 
A retrospective chart review of 123 patients younger than 18 years, 
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who underwent CI  was conducted for identification of intra- and 
postoperative anesthesia-related complications.  Of the 123 CI 
procedures, eight patients had nine anesthesia-related 
complications, yielding a complication rate of 6.5% and included 
the following: postoperative wheezing/stridor (5 cases), 
laryngospasm (3 cases), and emesis during inhalational induction (1 
case). Divided by age group, 12 patients were <12 months with one 
complication (8%), 18 patients were between 1 and 2 years with 
one complication (5.6%), 35 patients were between 2 and 5 years 
with one complication (3%), 39 patients were between 5 and 12 
years with five complications (13%), and 19 patients were older 
than 12 years with no complication (0%). Logistic regression failed 
to identify a significant association of any collected variable(s) 
with the observed complications. The incidence of complications is 
similar to that previously reported in elderly patients (4.3%) 
(Pearson χ2, P = .523). General anesthesia is well tolerated by 
pediatric patients undergoing CI, even under 1 year of age. 
Significant perioperative complications are primarily respiratory, 
are usually free of long-term sequelae, and occur with an incidence 
similar to other reported age groups. 
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MATERIALS AND METHODS 
This study was conducted at the Institute of 
Otorhinolaryngology, Rajiv Gandhi Government General Hospital, 
Madras Medical College, Chennai-3 between March 2017- August 
2017 on 40 patients of ASA physical status I and II undergoing 
elective cochlear implantation under general anaesthesia. This 
study was done after Government General Hospital Ethical 
committee approval and a written informed consent obtained from 
all the patients parent/guardian included in this study. 
STUDY DESIGN 
This study was done in a prospective double blinded 
randomized manner. Each group consisted of twenty patients. 
Group-D 
Patients in this group received loading dose of 
Dexmedetomidine 0.4mcg/kg and maintenance dose of 
Dexmedetomidine 0.4mcg/kg/hr through intravenous infusion. 
Group-F 
Patients in this group received loading dose of Fentanyl 
1mcg/kg and maintenance dose of Fentanyl 1mcg/kg/hr through 
intravenous infusion. 
 
37 
In this study Dexmedetomidine hydrochloride 100mcg/1ml 
and preservative free fentanyl 50mcg/1ml. All solutions were 
prepared under strict aseptic precautions by the OT incharge 
anaesthesiologist uninvolved in the observation of results.  
SELECTION OF CASES 
Inclusion Criteria 
 Age <6 years 
 ASA physical status I and II 
 Surgery: Elective Surgery 
 Who have given valid informed consent 
Exclusion Criteria 
 Not satisfying inclusion criteria 
 Patients with known allergy to Fentanyl or Dexmedetomidine 
 Fever 
 Upper respiratory tract infection 
 Coagulopathy 
 Prolonged QT interval 
 Ventricular arrhythmia 
 Congenital abnormalities. 
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PRE ANAESTHETIC EVALUATION 
Patients included in this study underwent preoperative  
evaluation which included the following. 
HISTORY 
History of previous surgery, underlying medical illness and 
hospitalization. 
PHYSICAL EXAMINATION 
Vital Signs 
Body weight 
Examination of CVS, RS, CNS 
Airway Assessment 
INVESTIGATION 
Haemoglobin (Hb), BT, CT, Renal Function Test (RFT), 
ECG, Chest X-Ray, Blood grouping and typing were done. Patient 
who satisified the inclusion criteria were explained about the nature 
of the study and the anaesthetic procedures and written informed 
consent were obtained from all patients parent/ guardian included in 
the study. 
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SENSITIVITY TEST 
Skin wheal sensitivity test was done for all patients half an 
hour before surgery. Pulse rate, BP, SPO2 was recorded. 
TECHNIQUE 
In the OT equipment for airway management and emergency 
drugs were kept ready. Patient was shifted to OT. The patient was 
placed on the operating table after checking the horizontal position. 
ECG, NIBP, SPO2 were connected to the patient. Preoperative 
baseline systolic and diastolic BP, HR, SPO2 were recorded. 
Preoxygenation with 100% oxygen for 3mins was done. 
Premedication was done with Inj.Glycopyrrolate IV 0.01mg/kg and 
Inj.Dexamethasone IV 0.15mg/kg. The anaesthesiologist who were 
unaware of the drugs performed induction and made observations in 
all the patients involved in the study. This is followed by 
Inj.Propofol IV 2mg/kg and Inj.Atracurium IV 0.5mg/kg was done. 
After ventilation, direct laryngoscopy and endotracheal intubation 
was done in the sniffing position with appropriate size ETT and 
fixed after checking bilateral chest expansion and air entry.  
Anaesthesia was maintained using a mixture of N2O and O2 in the 
ratio of 2:2, 2% seroflurane and through IV infusion maintenance 
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dose of test drug was started by the anesthesiologist unaware of it. 
All the following parameters were observed.  
VITAL SIGNS 
The Systolic and diastolic BP, PR& SPO2 were recorded 1 
minute after induction, 1 minute after intubation and thereby every 
15 minutes throughout the intra operative period. The above vital 
signs at the completion of surgery were noted. Hypotension defined 
as fall in systolic BP >30% from baseline or MAP <60mm of Hg. 
This was managed with Inj.Ephedrine 6mg increment. Bradycardia 
was defined as heart rate <50/mt and this was managed with 
Inj.Atropine 0.01mg/kg IV. Blood loss more than the allowable loss 
was replaced with blood. 
QUALITY OF THE SURGICAL FIELD 
0 No Bleeding 
1 Slight bleeding- Blood evacuation not necessary 
2 Slight bleeding- sometimes blood has to be evacuated 
3 Low bleeding- blood loss to be often evacuated operative 
field is visible for some seconds after evacuation. 
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4 Average bleeding- blood has to be often evacuated. 
Operative field is visible only right after evacuation. 
5 High bleeding- constant blood evacuation is needed. 
Sometimes bleeding exceed evacuation. Surgery is hardly possible. 
POST OPERATIVE ASSESSMENT 
Post operative recovery time was assessed by modified 
Aldrete recovery score and assessment of post operative pain by 
FLACC behavioral pain assessment scale and need for post 
operative analgesia was assessed. 
MODIFIED ALDRETE RECOVERY SCORE 
Variables Evaluated 
Activity  
Able to move four extremities on command. 2 
Able to move two extremities on command. 1 
Able to move no extremities on command 0 
Breathing  
Able to breathe deeply and cough freely 2 
Dyspnea 1 
Apnea 0 
Circulation  
Systemic blood pressure <=20% of the Preanesthetic 2 
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Variables Evaluated 
level 
Systemic blood pressure is 20% to 50% Of the 
preanesthetic level 
1 
Systemic blood pressure >=50% of the Preanesthetic 
level 
0 
Conciousness  
Fully awake 2 
Arousable 1 
Not responding 0 
Oxygen saturation (pulse oximetry)  
>92% while breathing room air 2 
Needs supplemental oxygen to maintain saturation 
>90% 
1 
<90% with supplemental oxygen 0 
 
FLACC SCALE  
FACE 
Score 0 if the patient has a relaxed face,makes eye 
contact,shows interest in surroundings. 
Score 1 if the patient has a worried facial expression,with 
eyebrows lowered, eyes partially closed, cheeks raised,mouth 
pursed. 
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Score 2 if the patient has deep furrows in the forehead,closed 
eyes, an open mouth, deep lines around nose and lips. 
LEGS 
Score 0 if the muscle tone and motion in the limbs are 
normal. 
Score 1 if the patient has increased tone,rigidity or tension; if 
there is intermittent flexion or extension of the limbs. 
Score 2 if the patient has hypertonicity,the legs are pulled 
tight,there is exaggerated flexion or extension of the limbs,tremors. 
ACTIVITY 
Score 0 if the patient moves easily and freely,normal activity 
or restrictions. 
Score 1 if the patient shifts positions, appears hesitant to 
move, demonstrates guarding, a tense torso, pressure on a body 
part. 
Score 2 if the patient is in a fixed position,rocking; 
demonstrates side to side head movement or rubbing of a body part. 
CRY 
Score 0 if the patient has no cry or moan, awake or asleep.  
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Score 1 if the patient has occasional moans, cries, whimpers, 
sighs. 
Score 2 if the patient has frequent or continuous moans, cries, 
grunts. 
CONSOLABILITY 
Score 0 if the patient is calm and does not require consoling.  
Score 1 if the patient responds to comfort by touching or 
talking in 30 seconds to 1 minute. 
Score 2 if the patient requires constant comforting or is 
inconsolable. 
INTERPRETING THE BEHAVIORAL SCORE 
Each category is scored on the 0-2 scale, which results in a 
total score of 0-10. 
0 = Relaxed and comfortable 
1-3 = Mild discomfort 
4-6 = Moderate pain 
7-10 = severe discomfort or pain or both. 
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OBSERVATION AND RESULTS 
This study was conducted at the Institute of Anaesthesiology 
and Critical care,Chennai. Forty(40) patients were included in this 
double blinded randomized controlled study. The patients were 
divided into two groups, group D and group F. Patients in group D 
received loading dose 0.4 mcg/kg and maintenance dose 0.4 
mcg/kg/hr and patients in group F received loading dose 1 mcg/kg 
and maintenance dose 1 mcg/kg/hr through intravenous infusion.  
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STATISTICS 
Descriptive statistics was done for all data and were reported 
in terms of mean values and percentages. Suitable statistical tests of 
comparison were done. Continuous variables were analysed with 
the unpaired t test.. Categorical variables were analysed with the 
Chi-Square Test and Fisher Exact Test. Statistical significance was 
taken as P < 0.05. The data was analysed using SPSS version 16 
and Microsoft Excel 2007. 
AGE  
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Age Groups Group D % Group F % 
2 years 7 35.00 6 30.00 
3 years 10 50.00 6 30.00 
4 years 3 15.00 6 30.00 
5 years 0 0.00 2 10.00 
Total 20 100.00 20 100.00 
 
Age Distribution Group D Group F 
Mean 2.80 3.20 
SD 0.70 1.01 
P value  Unpaired t Test 0.1516 
It is evident from the age distribution table that most of the 
group dexmedetomidine subjects were 3 years old (50%) with a 
mean age of 2.80 years. Similarly in group fentanyl majority were 
in same age group (30%) with a mean age of 3.20 years. 
(p=0.1516). The data subjected to unpaired t test reveals the 
existence of statistically insignificant association between age 
distribution and intervention groups (p > 0.05) 
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GENDER  
 
Gender Status Group D % Group F % 
Male 10 50.00 13 65.00 
Female 10 50.00 7 35.00 
Total 20 100.00 20 100.00 
P value Fishers Exact Test 0.3617 
It is evident from the gender status table that most of the 
group dexmedetomidine subjects were males (50%) and in group 
fentanyl majority belonged to same gender (63%) (p=0.3617). The 
data subjected to fishers exact test reveals the existence of 
statistically insignificant association between gender status and 
intervention groups (p > 0.05) 
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HR 
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Heart Rate Distribution 
Group D Group F P value 
Unpaired  
t Test Mean SD Mean SD 
Baseline 130.90 12.53 131.31 12.53 0.9465 
1min After Induction 125.25 11.17 128.16 11.17 0.1771 
1 min  After Intubation 129.50 12.56 133.41 12.56 0.8468 
15 min 123.60 8.59 127.81 8.59 0.8722 
30 min 121.95 8.63 125.86 8.63 0.8304 
45 min 120.95 10.17 124.06 10.17 0.8617 
1 Hr 118.20 10.44 122.76 10.44 0.5486 
1.15 Hr 115.85 11.60 120.81 11.60 0.4924 
1.30 Hr 114.65 11.46 118.31 11.46 0.3355 
1.45 Hr 112.60 10.78 116.31 10.78 0.2589 
2 Hr 110.20 11.98 115.61 11.98 0.8602 
2.15 Hr 108.45 11.33 113.71 11.33 0.8186 
2.5 Hr 106.70 9.98 111.81 9.98 0.7148 
2.45 Hr 108.00 9.72 111.31 9.72 0.3524 
3 Hr 107.70 9.91 110.71 9.91 0.5463 
3.15 Hr 108.40 10.55 111.60 10.55 0.3907 
3.5 Hr 108.82 11.01 112.07 11.01 0.5797 
3.45 Hr 109.29 8.46 111.96 8.46 0.6821 
4 Hr 109.67 0.00 111.76 0.00 0.4438 
4.15 Hr 100.00 0.00 112.16 0.00 0.7787 
Post Operative 108.60 8.27 112.81 8.27 0.3159 
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It is evident from the heart rate distribution table that most of 
the group dexmedetomidine subjects had a mean overall heart rate 
of 114.87 beats per min. Similarly in group fentanyl majority had a 
mean overall heart rate of 117.65 beats per min. (p=0.0674). The 
data subjected to unpaired t test reveals the existence of statistically 
insignificant association between heart rate distribution and 
intervention groups (p > 0.05).  
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SBP 
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Systolic Blood  
Pressure Distribution 
Group D Group F P value 
Unpaired  
t Test Mean SD Mean SD 
Baseline 107.15 6.09 107.91 6.09 0.1404 
1min After Induction 98.60 5.89 103.89 5.89 0.9271 
1 min  After Intubation 105.75 4.30 111.29 4.30 0.4171 
15 min 104.15 5.34 108.14 5.34 0.5057 
30 min 102.25 6.22 105.24 6.22 0.3491 
45 min 101.45 5.61 103.29 5.61 0.3067 
1 Hr 100.55 5.60 101.94 5.60 0.2206 
1.15 Hr 99.00 7.33 101.49 7.33 0.1412 
1.30 Hr 97.60 6.68 100.29 6.68 0.1468 
1.45 Hr 97.90 5.67 98.49 5.67 0.2063 
2 Hr 96.70 5.97 97.74 5.97 0.1361 
2.15 Hr 96.90 6.71 97.19 6.71 0.1768 
2.5 Hr 96.50 6.66 96.14 6.66 0.149 
2.45 Hr 96.25 7.95 96.89 7.95 0.1447 
3 Hr 97.25 6.75 98.19 6.75 0.1486 
3.15 Hr 96.40 6.29 98.94 6.29 0.0132 
3.5 Hr 96.12 7.56 100.85 7.56 0.0108 
3.45 Hr 97.14 11.57 102.34 11.57 0.0982 
4 Hr 98.00 0.00 104.94 0.00 >0.9999 
4.15 Hr 100.00 0.00 105.94 0.00 >0.9999 
Post Operative 96.60 7.96 101.54 7.96 0.1754 
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It is evident from the systolic blood pressure distribution 
table that most of the group dexmedetomidine subjects had a mean 
overall SBP of 98.76 mm Hg. Similarly in group fentanyl majority 
had a mean overall SBP of 101.66 mm Hg. (p= 0.0756). The data 
subjected to unpaired t test reveals the existence of statistically 
insignificant association between SBP distribution and intervention 
groups (p > 0.05).  
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DBP 
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Diastolic Blood  
Pressure Distribution 
Group D Group F P value 
Unpaired  
t Test Mean SD Mean SD 
Baseline 66.00 3.47 66.20 3.47 0.8788 
1min After Induction 59.40 4.21 62.76 4.21 0.7471 
1 min  After Intubation 66.00 3.97 68.16 3.97 0.2276 
15 min 62.90 5.50 65.01 5.50 0.2286 
30 min 61.45 6.02 63.16 6.02 0.2138 
45 min 60.00 5.72 61.31 5.72 0.0505 
1 Hr 58.40 6.50 60.61 6.50 0.0901 
1.15 Hr 58.35 7.19 60.11 7.19 0.3321 
1.30 Hr 57.90 6.61 59.41 6.61 0.3654 
1.45 Hr 56.50 6.38 58.11 6.38 0.0744 
2 Hr 55.90 7.02 57.96 7.02 0.679 
2.15 Hr 56.00 5.87 57.41 5.87 0.3063 
2.5 Hr 56.40 4.31 56.71 4.31 0.1511 
2.45 Hr 56.00 4.09 56.81 4.09 0.0766 
3 Hr 56.80 4.62 58.21 4.62 0.0439 
3.15 Hr 55.20 4.13 58.88 4.13 0.1038 
3.5 Hr 54.59 4.37 59.25 4.37 0.2023 
3.45 Hr 55.43 5.13 62.76 5.13 0.1236 
4 Hr 58.67 0.00 70.16 0.00 >0.9999 
4.15 Hr 70.00 0.00 73.16 0.00 >0.9999 
Post Operative 55.10 5.02 59.91 5.02 0.2822 
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It is evident from the diastolic blood pressure distribution 
table that most of the group dexmedetomidine subjects had a  mean 
overall DBP of 58.55 mm Hg. Similarly in group fentanyl majority 
had a mean overall DBP of 60.49 mm Hg. (p= 0.0853). The data 
subjected to unpaired t test reveals the existence of statistically 
insignificant association between DBP distribution and intervention 
groups (p > 0.05).  
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MAP 
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Mean Arterial Pressure  
Distribution 
Group D Group F P value 
Unpaired  
t Test Mean SD Mean SD 
Baseline 79.55 3.72 81.16 3.72 0.2849 
1min After Induction 72.40 4.33 77.21 4.33 0.08 
1 min  After Intubation 79.20 3.56 83.27 3.56 0.7917 
15 min 76.65 5.17 80.05 5.17 0.9328 
30 min 75.10 5.83 78.00 5.83 0.8389 
45 min 73.80 5.36 76.00 5.36 0.5012 
1 Hr 72.55 5.84 75.11 5.84 0.771 
1.15 Hr 71.85 7.24 74.69 7.24 0.8249 
1.30 Hr 71.10 6.53 73.84 6.53 0.8496 
1.45 Hr 70.35 5.96 72.48 5.96 0.7245 
2 Hr 69.55 6.26 72.21 6.26 0.3226 
2.15 Hr 69.65 5.55 71.69 5.55 0.1958 
2.5 Hr 69.80 4.18 70.69 4.18 0.6827 
2.45 Hr 69.45 4.71 71.11 4.71 0.5428 
3 Hr 70.40 4.43 72.42 4.43 0.8866 
3.15 Hr 69.00 4.26 73.10 4.26 0.8017 
3.5 Hr 68.53 4.65 73.80 4.65 0.7812 
3.45 Hr 69.29 6.23 76.56 6.23 0.7661 
4 Hr 72.00 0.00 84.16 0.00 >0.9999 
4.15 Hr 80.00 0.00 88.16 0.00 0.9999 
Post Operative 68.95 5.38 74.69 5.38 0.6199 
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It is evident from the mean arterial pressure distribution table 
that most of the group dexmedetomidine subjects had a mean 
overall MAP of 72.98 mm Hg. Similarly in group fentanyl majority 
had a mean overall MAP of 75.96 mm Hg. (p= 0.6734). The data 
subjected to unpaired t test reveals the existence of statistically 
insignificant association between MAP distribution and 
intervention groups (p > 0.05).  
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QUALITY SCALE 
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Quality Scale 
Distribution 
Group D Group F P value 
Unpaired  
t Test Mean SD Mean SD 
15 min 3.21 0.43 3.94 0.43 <0.0001 
30 min 3.21 0.42 4.00 0.42 <0.0001 
45 min 3.21 0.42 3.85 0.42 <0.0001 
1 Hr 3.21 0.42 3.80 0.42 0.0001 
1.15 Hr 3.37 0.50 3.25 0.50 0.4365 
1.30 Hr 3.26 0.45 3.20 0.45 0.6503 
1.45 Hr 3.16 0.37 3.15 0.37 0.9473 
2 Hr 3.00 0.00 3.05 0.00 0.3364 
2.15 Hr 3.00 0.00 3.05 0.00 0.3364 
2.5 Hr 3.00 0.00 3.00 0.00 >0.9999 
2.45 Hr 3.05 0.23 3.00 0.23 0.3112 
3 Hr 3.00 0.00 3.00 0.00 >0.9999 
3.15 Hr 3.00 0.00 3.00 0.00 >0.9999 
3.5 Hr 3.00 0.00 3.00 0.00 >0.9999 
3.45 Hr 3.00 0.00 3.00 0.00 >0.9999 
4 Hr 3.00 0.00 3.00 0.00 >0.9999 
4.15 Hr 3.00 0.00 3.00 0.00 >0.9999 
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It is evident from the quality of surgical field distribution 
table that most of the group dexmedetomidine subjects had a mean 
overall quality scale score of 2.63. Similarly in group fentanyl 
majority had a mean overall quality scale score of 2.76. (p= 
<0.0001).  
The decreased the mean quality scale score measurement in 
group dexmedetomidine compared to group fentanyl is statistically 
significant between the period of 15 minutes to 1 hour 
intraoperatively. The meaningful decrease is by 18% with a mean 
difference of 0.69.  The data subjected to unpaired t test reveals the 
existence of statistically significant association between quality 
scale score distribution and intervention groups (p < 0.05).  This 
difference is true and significant and has not occurred 
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POSTOPERATIVE RECOVERY TIME BY MAS 
 
Postoperative Recovery  
Time by MAS Groups 
Group D % Group F % 
≤ 480 secs 1 5.00 1 5.00 
481-540 secs 6 30.00 2 10.00 
541-600 secs 9 45.00 8 40.00 
> 600 secs 4 20.00 9 45.00 
Total 20 100.00 20 100.00 
 
Postoperative Recovery  
Time by MAS Distribution 
Group D Group F 
Mean 564.25 593.00 
SD 50.27 51.33 
P value Unpaired t Test 0.0441 
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It is evident from the postoperative recovery time by MAS 
distribution table that most of the group dexmedetomidine subjects 
had a mean postoperative recovery time of 564.25 seconds. 
Similarly in group fentanyl majority had a mean postoperative 
recovery time of 593 seconds. (p= 0.0441).  
The decreased the mean postoperative recovery time 
measurement in group dexmedetomidine compared to group 
fentanyl is statistically with a meaningful decrease is of 5% and 
with a mean difference of 28.75 seconds.  The data subjected to 
unpaired t test reveals the existence of statistically significant 
association between postoperative recovery time distribution and 
intervention groups (p < 0.05). This difference is true and 
significant and has not occured 
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FLACC- BPAS 
 
 
FLACC- BPAS Status Group D % Group F % 
Score 0 19 95.00 14 70.00 
Score 1 1 5.00 6 30.00 
Total 20 100.00 20 100.00 
P value Fishers Exact Test 0.0449 
It is evident from the FLACC - BPS status table that 95% of 
the group dexmedetomidine subjects had FLACC – BPS score 0. 
Similarly 70% of group fentanyl majority had FLACC – BPS score 
0. (p= 0.0449).  
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The increased incidence of FLACC – BPS score 0 in group 
dexmedetomidine compared to group fentanyl is statistically with a 
meaningful increase of 26% and with a percentage difference of 
25.00 points.  The data subjected to fishers exact test reveals the 
existence of statistically significant association between 
postoperative recovery time distribution and intervention groups (p 
< 0.05). This difference is true and significant and has not occurred 
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RESCUE ANALGESIA 
 
Rescue Analgesia Status Group D % Group F % 
No 19 95.00 18 90.00 
Yes 1 5.00 2 10.00 
Total 20 100.00 20 100.00 
P value Fishers Exact Test 0.6186 
It is evident from the rescue analgesia status table that most 
of the group dexmedetomidine subjects did not need recue 
analgesia (95%) and in group fentanyl majority too did not need 
recue analgesia (90%) (p=0.6186). The data subjected to fishers 
exact test reveals the existence of statistically insignificant 
association between did not need recue analgesia status and 
intervention groups (p > 0.05) 
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DISCUSSION 
General Anaesthesia is a commonly used anaesthetic 
technique for cochlear Implantation surgeries in paediatric patients.  
In this study,intravenous infusion dose of Dexmedetomidine 
0.4mcg/kg/hr versus FENTANYL 1mcg/kg/hr and their post 
operative recovery time was studied in 40 patients undergoing 
elective cochlear Implantation surgery. 
POST OPERATIVE RECOVERY TIME 
The mean post operative recovery time for Dexmedetomidine 
group was 564.25 seconds and for Fentanyl group was 593 
seconds.Patients in the dexmedetomidine group have significantly 
and consistently quicker post operative recovery time.  
Mohammed Hafez El Saied et al who compared the 
intravenous infusion dose of Dexmedetomidine 0.4mcg/kg/hr 
versus Fentanyl 1mcg/kg/hr in post operative recovery time and 
observed that recovery time was significantly shorter for the 
patients in D group than in F group. 
Gupta N et al did a comparative study between 
dexmedetomidine and volume matched saline (placebo) and found 
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that intraoperative use of Dexmedetomidine has a shorter recovery 
time. 
Goyal S et al who compared the effect of 0.25mcg/kg/hr 
maintenance dose of dexmedetomidine vs fentanyl 0.5mcg/kg/hr 
and observed that dexmedetomidine has better recovery profile than 
fentanyl. 
POST OPERATIVE PAIN 
In our study, the increased incidence of FLACC- BPS Score 0 
in group D compared to group F is statistically with a meaningful 
increase of 26% and we conclude that post operative pain was 
significantly and consistently lower with dexmedetomidine 
compared to fentanyl. 
   Mohamed Hafez El Saied et al who compared the IV 
infusion dose of Dexmedetomidine 0.4mcg/kg/hr versus Fentanyl 
1mcg/kg/hr in post operative pain and observed that post operative 
pain were not different between the two groups. 
        Gupta N et al did a comparative study between 
dexmedetomidine and volume matched saline (placebo) and found 
that group D patients has reduced post operative pain. 
       Hwang W, Lee J, Park J, Joo J et al who compared the effect of 
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0.01-0.02 mcg/kg/min dexmedetomidine vs remifentanyl 0.01-0.02 
mcg/kg/min in post operative pain control and found that 
Dexmedetomidine displayed superior efficacy in alleviating pain 
and in post operative pain management. 
INTRA OPERATIVE HEMODYNAMICS 
In our study, dexmedetomidine subjects had a mean overall 
heart rate of 114.87 beats per minute and fentanyl subjects had a 
mean overall heart rate of 117.65 beats per min. 
Dexmedetomidine group had a mean overall Systolic Blood 
Pressure of 98.76 mmHg and Fentanyl group had a mean overall 
Systolic Blood Pressure of 101.66 mmHg. 
Dexmedetomidine group had a mean overall Diastolic Blood 
Pressure of 58.55 mmHg and Fentanyl group had a mean overall 
Diastolic Blood Pressure of 60.49 mmHg. 
Dexmedetomidine group had a mean overall Mean Arterial 
Pressure of 72.98 mmHg and fentanyl group had a mean overall 
Mean Arterial Pressure of 75.96 mmHg. 
We conclude that there is a existence of statistically 
insignificant association between Heart  Rate, Systolic Blood 
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Pressure, Diastolic Blood Pressure, Mean Arterial Pressure 
distribution between dexmedetomidine and fentanyl group. 
Mohamed Hafez El Saied et al who compared the IV infusion 
dose of dexmedetomidine 0.4 mcg/kg/hr versus Fentanyl 
1 mcg/kg/hr in intra operative hemodynamics and observed that 
group D showed a decreased heart rate and mean arterial pressure 
than fentanyl group and was better in inducing deliberate 
hypotension and statistically significant. 
Gupta N et al did a comparative study between 
dexmedetomidine and volume matched saline (placebo) and found 
that dexmedetomidine group had bradycardia and hypotension and 
statistically significant. 
Goyal S et al who compared the effect of 0.25 mcg/kg/hr 
maintenance dose of Dexmedetomidine vs fentanyl 0.5 mcg/kg/hr 
and observed that mean intraoperative hemodynamics was less in 
group D compared to group F with significant p value. 
QUALITY OF THE SURGICAL FIELD 
In our study,mean overall quality scale for Dexmedetomidine 
was 2.63 and for Fentanyl was 2.76 and found that 
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dexmedetomidine has better quality of the surgical field compared 
to Fentanyl. 
Mohamed Hafez El Sailed et al who compared the IV infusion 
dose of Dexmedetomidine 0.4 mcg/kg/hr versus Fentanyl 1 
mcg/kg/hr in quality of the surgical field and observed that group D 
has better quality of the surgical field compared to Fentanyl 
infusion. 
Passaint Fahim Hassan, Amany Hassan Saleh et al who 
compared the effect of 0.4 mcg/kg/hr dexmedetomidine continuous 
infusion versus 10mg/kg/hr Magnesium sulfate continuous infusion 
in providing better quality of the surgical field and observed that 
dexmedetomidine have superior effect on the surgical field.  
Sabry Mohamed Amin et al who conducted the study to 
determine the efficacy of 0.2-0.5mcg/kg/hr continuous infusion of 
Dexmedetomidine versus 100- 300 mcg/kg/min continuous infusion 
of Esmolol and observed that Dexmedetomidine ensured good 
surgical field during surgery. 
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NEED FOR RESCUE ANALGESIA 
In our study,there is no need for post operative analgesia in 
both groups. 
Mohamed Hafez El Saied et al who compared the IV infusion 
dose of Dexmedetomidine 0.4mcg/kg/hr versus Fentanyl 1 
mcg/kg/hr and observed that group D has reduced need for pain 
medication in the PACU. 
Goyal S et al who compared the effect of 0.25 mcg/kg/hr 
maintenance dose of Dexmedetomidine vs Fentanyl 0.5 mcg/kg/hr 
and observed that group D has reduced need for post operative pain 
management. 
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SUMMARY 
This double blinded prospective randomized controlled trial 
was designed to compare the post operative recovery time by 
MAS,as well as to assess the post operative pain by FLACC, intra 
operative hemodynamics,quality of the surgical field,need for 
rescue analgesia of Dexmedetomidine versus Fentanyl given 
intravenous infusion for paediatric patients scheduled for cochlear 
Implantation surgery, patients receiving IV fentanyl Infusion served 
as the control. 
The following observations were made : Dexmedetomidine 
have significantly and consistently quicker post operative recovery 
time. 
Dexmedetomidine have lower post operative pain when 
compared to Fentanyl. Dexmedetomidine have lower intra operative 
hemodynamics when compared to Fentanyl though statistically 
insignificant. Dexmedetomidine have better quality of the surgical 
field when compared with Fentanyl. Dexmedetomidine group has 
reduced need for post operative pain management. 
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CONCLUSION 
  Dexmedetomidine infusion in Cochlear Implantation in 
paediatric patients seems to be a good alternative to Fentanyl 
infusion since it produces quicker post operative recovery time and 
reducing post operative pain with better quality of the surgical field 
and reduced need for rescue analgesia.Dexmedetomidine was well 
tolerated with no clinically significant effects on blood pressure or 
heart rate. 
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Age 
Sex
Age/ 
Sex
Basline
IP NO HR SBP DBP MAP
Qua.Sc
ale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
1 pradeep 3 1 53654 126 100 60 73 116 90 54 66 122 111 62 78 101 98 58 71
2 muthulakshmi 3 2 52265 116 100 60 73 111 90 54 66 126 110 72 85 120 111 76 88
3 yuvasree 3 2 49326 128 100 60 73 126 88 52 64 138 126 88 100 134 121 82 95
4 rashika 4 2 46071 152 118 70 86 146 111 68 82 148 118 76 90 141 112 72 85
5 astika 2 2 61367 156 100 60 73 145 88 54 65 150 100 62 75 141 98 60 73
6 yogesh 4 1 53912 144 118 76 90 138 102 64 77 140 108 72 84 136 110 72 85
7 vishnu 2 1 50516 136 111 68 82 130 101 58 72 134 109 66 80 126 111 64 80
8 movendran 3 1 53654 126 98 64 75 119 90 54 66 121 94 66 75 118 92 60 71
9 yashini 2 2 54675 121 102 62 75 116 98 56 70 120 102 62 75 114 101 58 72
10 ramesh 3 1 60746 132 118 74 89 128 104 64 77 133 110 68 82 126 109 58 75
11 babu 2 1 62734 136 106 68 81 128 99 60 73 132 102 64 77 128 102 62 75
12 priya 4 2 59432 128 106 66 79 124 99 62 74 126 102 62 75 121 100 60 73
13 darshan 2 1 54432 118 116 66 83 114 111 64 80 118 114 68 83 114 112 64 80
14 ganesh 3 1 59432 134 106 66 79 130 104 62 76 132 106 62 77 126 102 58 73
15 vijaya 2 2 60024 126 104 66 79 122 98 56 70 124 102 62 75 119 102 58 73
16 ramkumar 3 1 61240 138 118 72 87 132 108 64 79 136 106 62 77 132 112 60 77
17 indira 3 2 58432 118 104 64 77 114 99 62 74 116 102 64 77 114 102 62 75
18 rani 2 2 58439 128 111 62 78 124 99 58 72 126 99 62 74 121 98 62 74
19 kasi 3 1 58646 134 108 68 81 126 99 62 74 130 98 56 70 126 96 54 68
20 revathi 3 2 56943 121 99 68 78 116 94 60 71 118 96 64 75 114 94 58 70
S. No Name
GROUP-D
Intra Operative - 
1min after induction 1 min after intubation 15 min
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
S. No
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
110 100 60 73 3 115 100 67 78 3 114 100 60 73 3 111 97 63 74 4 111 95 62 73 4
118 106 71 83 3 114 104 68 80 3 111 102 64 77 3 111 101 64 76 4 106 101 66 78 4
130 120 82 95 3 130 118 74 89 3 124 116 74 88 3 124 110 72 85 3 121 109 68 82 3
3 136 108 70 83 3 132 108 71 83 3 131 106 68 81 3 126 104 64 77 3 124 102 62 75 3
3 140 98 60 73 3 136 96 58 71 4 136 94 56 69 4 132 92 56 68 4 130 90 54 66 4
3 134 108 68 81 3 132 104 64 77 3 132 104 66 79 3 128 106 62 77 4 126 102 60 74 4
124 108 62 77 3 124 108 60 76 3 120 106 60 75 3 114 104 58 73 3 114 102 54 70 3
116 92 58 69 116 94 56 69 114 94 58 70 109 94 56 69 109 92 54 67
3 111 98 56 70 3 110 96 54 68 3 99 96 52 67 3 98 94 54 67 3 98 92 56 68 3
3 124 108 60 76 3 124 106 62 77 3 118 104 60 75 3 120 106 60 75 3 122 102 62 75 3
3 124 99 60 73 3 122 98 58 71 3 122 98 56 70 3 124 96 56 69 3 118 94 54 67 3
3 116 99 58 72 3 118 98 56 70 3 118 96 56 69 3 114 96 54 68 4 112 94 58 70 4
3 116 109 62 78 3 114 108 62 77 3 111 108 56 73 4 109 104 58 73 4 108 106 58 74 3
3 128 99 58 72 3 124 96 56 69 3 120 96 54 68 3 122 94 58 70 3 118 94 58 70 3
3 118 99 54 69 3 118 98 54 69 3 114 94 52 66 3 106 94 56 69 3 108 96 54 68 3
3 130 110 60 77 4 132 108 54 72 4 126 106 56 73 3 121 104 56 72 3 122 104 54 71 3
112 100 58 72 4 110 102 56 71 4 112 99 54 69 4 114 98 56 70 3 112 98 58 71 3
4 118 98 60 73 4 116 99 58 72 4 114 102 58 73 4 114 104 56 72 3 112 99 56 70 3
4 122 96 56 69 4 122 98 56 70 3 118 98 54 69 3 116 94 56 69 4 116 94 58 70 3
4 112 90 56 67 3 110 90 56 67 3 110 92 54 67 3 104 88 52 64 3 106 86 52 63 3
GROUP-D
1.30 Hr
Intra Operative - 
15 min 30 min 45 min 1 Hr 1.15 Hr
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
S. No
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR
114 100 56 71 4 100 100 58 72 3 96 100 60 73 3 85 95 60 72 3 102 90 54 66 3 106
106 101 58 72 3 101 99 54 69 3 99 99 54 69 3 94 98 56 70 3 92 101 54 70 3 92
120 108 66 80 3 118 108 66 80 3 118 110 64 79 3 116 110 62 78 3 116 110 62 78 3 118
124 102 62 75 3 116 98 60 73 3 112 96 60 72 3 111 96 58 71 3 114 94 60 71 3 112
128 90 54 66 3 130 94 56 69 3 130 90 58 69 3 126 92 58 69 3 124 92 58 69 3 126
124 98 58 71 3 122 96 56 69 3 122 96 56 69 3 124 96 54 68 3 126 94 58 70 3 122
112 99 56 70 3 110 98 54 69 3 110 98 54 69 3 109 99 54 69 3 111 98 52 67 3 108
104 96 52 67 102 96 52 67 104 94 54 67 101 94 54 67 99 92 56 68 98
96 96 58 71 3 96 99 58 72 3 94 102 62 75 3 94 106 62 77 3 96 102 60 74 3 102
118 104 62 76 3 116 98 60 73 3 112 98 56 70 3 112 96 54 68 3 110 102 52 69 3 112
116 98 52 67 3 116 98 52 67 3 118 96 54 68 3 112 96 58 71 3 114 94 56 69 4 109
106 92 56 69 3 108 92 54 67 3 106 96 52 67 3 104 98 58 71 3 104 94 58 70 3 102
110 104 56 72 4 104 102 54 70 3 102 99 52 68 3 102 98 54 69 3 104 102 54 70 3 99
114 98 56 70 4 116 92 54 67 3 110 92 52 65 3 114 94 54 67 3 116 96 56 69 3 109
108 96 54 68 3 106 88 52 64 3 104 96 54 68 3 102 94 54 67 3 108 94 52 66 3 110
118 102 52 69 3 120 96 52 67 3 114 96 54 68 3 112 98 56 70 3 110 96 58 71 3 110
104 96 58 71 3 106 96 56 69 3 102 94 56 69 3 99 92 54 67 3 98 96 52 67 3 98
110 96 54 68 3 99 94 60 71 3 98 94 58 70 3 106 92 58 69 3 108 92 60 71 3 108
114 96 58 71 3 114 102 56 71 3 116 104 54 71 3 112 96 52 67 3 110 94 52 66 3 114
106 86 52 63 3 104 88 54 65 3 102 88 56 67 3 99 90 58 69 3 98 92 56 68 3 99
3 Hr1.45 Hr 2 Hr 2.15 Hr 2.5 Hr 2.45 Hr
Intra Operative - 
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
S. No
SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.Sc
ale
HR SBP DBP MAP
Qua.S
cale
HR SBP
100 70 80 3 101 90 60 70 100 90 58 69 109 90 54 66 109 100 70 80 100 100
102 54 70 3 96 104 54 71 3 98 104 56 72 3 3 3
108 64 79 3 118 106 60 75 3 116 104 58 73 3 116 102 62 75 3 3
96 61 73 3 114 94 62 73 3 3
94 56 69 3 128 94 54 67 3 126 92 58 69 3 3 3
96 56 69 3 118 98 58 71 3 116 98 56 70 3 116 96 54 68 3 3
96 56 69 3 106 98 54 69 3 114 98 54 69
90 54 66 104 94 52 66 102 92 54 67
99 58 72 3 104 98 56 70 3 104 98 54 69 102 96 54 68 106 96 52 67
102 52 69 3 112 98 52 67 3 114 98 54 69 3
92 54 67 3 112 98 54 69 3 114 96 52 67 116 96 56 69 114 98 54 69
94 62 73 3 104 94 58 70 3 106 92 56 68 3
104 56 72 3 98 96 54 68 96 96 52 67 96 98 54 69
98 52 67 3 114 98 54 69 3 112 94 54 67
96 52 67 3 102 92 54 67 3 102 94 52 66 3
102 54 70 3 112 102 52 69 3 114 104 54 71 3 110 102 54 70 3 3
98 54 69 3 99 98 52 67 3 3
94 61 72 3 112 94 56 69 3 112 96 54 68
96 54 68 3 112 96 54 68 3
88 56 67 3 102 86 54 65 3 104 88 52 64 3
3 Hr 3.15 Hr 3.5 Hr 3.45 Hr 4 Hr 4.15 Hr
Intra Operative - 
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
S. No
DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
HR SBP DBP MAP
Qua.S
cale
Postop Recovery Time 
by MAS
FLACC- BPAS
Rescue analgesia 
and Antiemetics
70 80 106 104 66 79 9.25 mins 0 no
99 102 56 71 9.36 mins 0 no
3 118 108 60 76 9.04 mins 0 no
114 94 62 73 8.48 mins 0 no
128 92 56 68 8.32 mins 0 no
118 96 54 68 9.30 mins 0 no
112 98 52 67 8 mins 0 no
102 92 52 65 8.42 mins 0 no
102 94 56 69 9.38 mins 0 no
112 99 54 69 9.50 mins 0 no
112 96 54 68 9 mins 0 no
104 94 56 69 8.46 mins 0 no
94 96 56 69 9.40 mins 0 no
112 94 52 66 10.26 mins 0 no
104 94 52 66 9.48 mins 0 no
112 99 52 68 10.56 mins 0 no
99 96 54 68 9.09 mins 0 no
108 98 54 69 10.06 mins 0 no
114 94 52 66 11.05 mins 0 no
102 92 52 65 8.04 mins 1
t.paracetamol per 
rectum
4.5 Hr4.15 Hr
Post Operative
Intra Operative - 
IP NO HR SBP DBP MAP
Qua. 
Scale
HR SBP DBP MAP
Qua. 
Scale
HR SBP DBP MAP
Qua. 
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
1 keerthana 4 2 46923 148 113 68 83 150 100 60 73 158 114 72 86 134 104 62 76 4 130 108 66 80 4
2 reginadevi 3 2 49328 129 116 67 83 121 100 60 73 138 116 74 88 140 112 71 85 4 138 110 68 82 4
3 omprakash 2 1 52946 160 118 68 85 148 110 64 79 150 112 66 81 138 116 74 88 136 116 72 87 4
4 kirthana 5 2 60187 156 112 68 83 140 110 70 83 158 116 72 87 138 118 76 90 4 136 114 72 86 4
5 anbu 2 1 35596 142 106 68 81 142 100 60 73 144 106 68 81 141 108 63 78 3 143 110 71 84 4
6 durga 2 2 35487 132 110 70 83 128 99 68 78 134 111 72 85 130 110 70 83 126 109 68 82 4
7 thiruvasan 4 1 35488 140 110 66 81 138 106 61 76 139 109 64 79 130 100 60 73 4 126 99 56 70 4
8 prasanna 2 1 55576 130 118 71 124 101 61 126 111 68 121 109 64 4 121 106 62 4
9 santhosh 3 1 54159 136 118 68 85 131 108 61 77 135 116 66 83 130 111 62 78 4 128 110 61 77 4
10 gomathi 4 2 61362 126 114 68 83 120 111 64 80 122 114 66 82 121 106 61 76 4 118 104 56 72 4
11 deepika 3 2 61124 121 118 62 81 121 111 60 77 118 114 64 81 116 111 61 78 4 116 106 54 71 4
12 mukilarasan 2 1 58462 116 109 61 77 111 99 56 70 114 100 60 73 112 99 58 72 4 111 90 58 69 4
13 saravanan 3 1 59462 124 118 68 85 119 116 62 80 126 118 66 83 124 116 64 81 4 120 111 61 78 4
14 diwakar 5 1 61650 120 99 61 74 118 98 56 70 122 109 66 80 121 106 60 75 4 116 104 60 75 4
15 sanjay 2 1 57432 118 101 64 76 116 100 62 75 124 112 66 81 121 110 61 77 4 121 101 56 71 4
16 gayathri 4 2 59652 128 111 60 77 126 99 56 70 132 114 66 82 126 110 61 77 4 124 99 58 72 4
17 nishanth 3 1 61374 131 118 68 85 130 111 61 78 134 114 66 82 132 110 60 77 4 130 109 56 74 4
18 ashwin 4 1 79876 116 101 61 74 116 99 56 70 121 109 62 78 120 101 56 71 4 116 99 56 70 4
19 durai 4 1 62459 126 111 71 84 121 110 70 83 124 114 74 87 116 111 71 84 4 118 110 68 82 4
20 prabhu 3 1 60012 124 114 66 82 120 111 64 80 126 118 62 81 122 116 62 80 4 120 111 61 78 4
15 min 30 min
GROUP-F
Intra Operative - 
S. No Name
Age 
Sex
Age/ 
Sex
1min after inductionBasline 1 min after intubation
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
S. No
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
130 110 70 83 4 128 106 68 80 4 126 104 62 76 4 128 110 68 82 3 128 110 68 82 3 128 114 72 86 3
136 109 66 80 4 138 109 68 82 3 139 112 61 78 3 133 110 60 77 4 130 106 58 74 3 130 98 56 70 3
121 112 70 84 4 124 111 68 82 4 126 111 68 82 3 124 110 64 79 4 121 109 62 78 3 126 109 62 78 3
134 100 60 73 3 134 100 70 80 4 136 110 72 85 4 136 112 74 87 3 124 100 70 80 3 126 100 72 81 3
154 111 71 84 4 151 112 70 84 4 147 118 78 91 3 143 108 71 83 3 141 106 71 83 3 142 102 70 81 3
124 108 64 79 4 120 104 64 77 4 120 106 60 75 3 118 106 60 75 3 116 102 58 73 3 118 101 58 72 3
124 98 54 69 4 124 94 52 66 4 118 90 51 64 3 116 88 54 65 3 116 90 51 64 3 116 88 52 64 3
118 106 60 4 116 104 58 4 116 104 56 3 114 102 54 3 110 101 52 4 106 99 51 3
125 109 61 77 4 125 109 62 78 4 124 108 61 77 4 120 104 56 72 3 119 101 54 70 3 118 102 56 71 3
116 101 54 70 4 116 101 56 71 3 110 98 56 70 3 109 99 56 70 4 109 99 54 69 3 104 102 54 70 3
110 104 52 69 4 110 104 52 69 3 106 99 51 67 3 101 98 54 69 3 96 98 56 70 3 96 98 56 70 4
111 92 56 68 3 106 92 56 68 4 99 91 54 66 4 99 92 52 65 3 98 92 52 65 3 98 92 51 65 3
118 110 58 75 4 118 104 56 72 3 116 102 54 70 3 118 99 54 69 4 114 99 52 68 3 114 96 52 67 3
114 102 58 73 4 114 98 56 70 4 110 98 56 70 3 106 94 54 67 3 106 92 52 65 3 101 92 51 65 3
118 98 56 70 4 118 98 54 69 4 116 98 54 69 3 112 99 54 69 3 112 99 51 67 3 110 101 50 67 3
121 99 58 72 4 122 98 54 69 4 122 96 56 69 3 118 96 56 69 3 116 94 54 67 4 116 94 54 67 3
130 104 56 72 4 126 104 52 69 4 126 100 54 69 3 121 101 51 68 3 121 99 54 69 3 120 99 54 69 3
116 98 54 69 3 114 98 52 67 4 111 94 51 65 4 106 94 51 65 3 106 92 52 65 3 104 92 51 65 3
118 106 64 78 4 114 104 61 75 4 114 104 60 75 3 111 101 60 74 3 114 98 56 70 4 112 96 54 68 3
120 110 61 77 4 114 110 60 77 4 111 108 64 79 3 110 104 62 76 3 106 104 62 76 3 104 101 60 74 3
1.45 Hr 2 Hr45 min 1 Hr 1.15 Hr 1.30 Hr
Intra Operative - 
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
S. No
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
122 102 66 78 3 114 96 57 70 3 107 86 50 62 3 109 106 68 80 3 3 3
126 98 54 69 3 125 96 54 68 3 124 98 56 70 3 120 100 56 71 3 111 101 58 72 3 116 104 60 75 3
126 108 64 79 3 124 104 60 75 3 121 104 62 76 3 120 102 61 75 3 119 102 62 75 3 118 104 64 77 3
126 110 74 86 3 110 100 66 77 3 108 100 65 77 3 108 102 66 78 3 102 106 68 81 3 104 104 64 77
138 100 61 74 4 131 98 65 76 3 132 99 61 74 3 131 94 58 70 3 138 91 54 66 3 133 90 51 64 3
119 110 56 74 3 121 116 58 77 3 122 118 60 79 3 121 118 61 80 3 120 114 60 78 3 120 116 58 77 3
114 86 54 65 3 116 88 52 64 3 118 90 58 69 3 120 91 56 68 3 121 94 60 71 3 3
108 88 54 3 110 89 56 3 111 91 54 3 114 101 51 3 116 102 52 3 3
116 101 54 70 3 111 98 54 69 3 111 99 52 68 3 112 98 52 67 3 114 99 54 69 3 3
106 101 52 68 3 102 101 51 68 3 106 108 58 75 3 108 106 60 75 3 106 110 61 77 3 104 111 61 78 3
94 99 58 72 3 94 101 58 72 3 96 104 54 71 3 98 104 56 72 3 104 102 58 73 3 3
99 94 54 67 3 99 94 54 67 3 101 91 54 66 3 94 91 56 68 3 98 92 56 68 3 99 92 58 69 3
109 94 51 65 3 109 94 54 67 3 106 94 51 65 3 106 96 52 67 3 3 3
99 91 54 66 3 98 90 54 66 3 98 90 56 67 3 99 92 58 69 3 104 94 61 72 3 3
104 104 50 68 3 104 104 52 69 3 99 108 54 72 3 92 99 56 70 3 94 99 54 69 3 96 101 54 70 3
111 92 54 67 3 111 92 51 65 3 114 92 51 65 3 110 94 52 66 3 106 94 51 65 3 108 96 54 68 3
118 96 56 69 3 118 94 58 70 3 116 98 58 71 3 114 99 60 73 3 116 104 60 75 3 118 101 61 74
101 94 51 65 3 101 91 52 65 3 102 91 54 66 3 102 94 54 67 3 99 94 56 69 3 3
111 96 54 68 3 114 94 51 65 3 110 94 51 65 3 109 92 56 68 3 114 98 58 71 3
104 101 54 70 3 101 104 54 71 3 101 104 54 71 3 104 106 52 70 3 106 104 56 72 3 104 102 54 70 3
3.15 Hr 3.5 Hr2.15 Hr 2.5 Hr 2.45 Hr 3 Hr
Intra Operative - 
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
S. No
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP
Qua.
Scale
HR SBP DBP MAP Qua.Scale
3 3 3 123 117 68 84
119 104 64 77 126 106 64 78
118 106 68 81 3 119 111 69 83 3 121 116 72 87 118 112 68 83
106 110 62 78
131 92 61 71 120 98 64 75
124 121 61 81 3 3 114 120 60 80
118 94 61 72
119 102 54
3 3 119 100 58 72
108 114 61 79
3 3 108 101 58 72
102 94 56 69
3 3 106 96 51 66
104 94 62 73
96 102 56 71
108 94 54 67 3 3 112 96 52 67
118 101 58 72
101 96 56 69
111 98 54 69
104 101 52 68
3.45 Hr 4 Hr 4.15 Hr 4.5 Hr
Intra Operative - Post Operative
12
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
S. No
Postop Recovery Time by MAS
FLACC- 
BPAS
Rescue analgesia and Antiemetics
9.15 mins 0 no
9.36 mins 0 no
8 mins 0 no
9.45 mins 0 no
9.56 mins 0 no
10.06 mins 0 no
10.26 mins 0 no
8.26 mins 0 no
9.16 mins 0 no
10.16 mins 1 paracetamol suppositories given
10.42 mins 0 no
10.46 mins 0 no
9.06 mins 0 no
10.02 mins 0 no
10.45 mins 0 no
11.02 mins 0 paracetamol suppositories given
9.50 mins 0 no
8.55 mins 0 no
9.50 mins 0 no
11.40 mins 0 no
Post Operative
